Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06102434 · ClinicalTrials.gov registry record · Early Phase 1
Safety Profile of Psilocybin for Cocaine Use Disorder
A Early Phase 1 study of Cocaine Use Disorder, sponsored by University of California, Los Angeles.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT06102434 is a Early Phase 1 study of Cocaine Use Disorder that is actively recruiting participants, run by University of California, Los Angeles. The registered enrollment target is 10 participants, below the 103-participant average among 26 other Cocaine Use Disorder trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06102434, a Early Phase 1 study of Cocaine Use Disorder, is actively recruiting participants, sponsored by University of California, Los Angeles.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to establish the safe administration of psilocybin in individuals with cocaine use disorder in terms of cardiovascular (e.g., heart rate) and subjective (e.g., mood) effects. The study's subject population consists of men and women between the ages of 21 and 55 from the Los Angeles area that meet criteria for cocaine use disorder and express an interest in ceasing cocaine use. 25 mg oral psilocybin will be administered to 10 individuals (separately) during a single laboratory visit. The laboratory visit will take place from 9 am until 3 pm within a comfortable, living room like environment. Within this study session room, participants will be accompanied by two clinicians. Participants will then consume the psilocybin capsule, and thereafter will be encouraged to lie down on a couch and introspect on the experience. At one-hour intervals following ingestion, participants will be tested briefly for changes in heart rate, blood pressure, and subjective effects. No blood draws, behavioral assessments, or neuroimaging is included in the study. Following the laboratory visit, investigators will check-in on participants remotely, after 48 hours, and 10, 50, and 90 days from the psilocybin session.
Conditions Studied
Interventions
- DRUG Psilocybin
Study Locations (1)
California
- University of California, Los Angeles - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2026-02-01 |
| Est. Completion | 2026-06 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06102434
The ClinicalTrials.gov registry entry for NCT06102434 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 103-participant average among 26 other Cocaine Use Disorder trials with a reported enrollment target (90% lower). The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cocaine Use Disorder appearing as the primary indexed condition, and to 1 intervention - of which Psilocybin is the first listed.
NCT06102434 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06102434 about?
NCT06102434 is a clinical study titled "Safety Profile of Psilocybin for Cocaine Use Disorder". The purpose of this study is to establish the safe administration of psilocybin in individuals with cocaine use disorder in terms of cardiovascular (e.g., heart rate) and subjective (e.g., mood) effects. The study's subject population consists of men and women between the ages of 21 and 55 from the ...
What is the current status of trial NCT06102434?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2026-02-01. Estimated completion is 2026-06.
What conditions does trial NCT06102434 study?
This clinical trial studies the following conditions: Cocaine Use Disorder.
What interventions are being tested in trial NCT06102434?
The interventions under investigation include: Psilocybin (DRUG).
Who is sponsoring clinical trial NCT06102434?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06102434 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cocaine Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cocaine and Pentoxifylline (BED IN 47)
RECRUITING · Early Phase 1
-
Behavioral Effects of Drugs (Inpatient): 43 (Opioids, Cocaine, n-Acetylcysteine)
RECRUITING · Early Phase 1
-
Imaging CRF X NOP Interactions in CUD
RECRUITING · Early Phase 1
-
[C-11]NPA PET-amphetamine in Cocaine Use Disorders
RECRUITING · Early Phase 1
-
Targeting Drug Memories With Methylphenidate
ACTIVE NOT RECRUITING · Early Phase 1
-
[11C]NOP-1A and Cocaine Use Disorders
COMPLETED · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.